Gene Validity Classification Summary

Gene/Disease Pair:

SLC25A20 : carnitine-acylcarnitine translocase deficiency

HGNC:1421 | MONDO_0008918
Mode of Inheritance: Autosomal recessive inheritance (HP:0000007)
Expert Panel: Fatty Acid Oxidation Disorders EP
SOP: Gene Clinical Validity Standard Operating Procedures (SOP), Version 6

Genetic Evidence
Case-Level Data
Evidence Type Case Information Type Guidelines Points PMIDs/Notes
Default Range Max Count Total Counted
Variant Evidence
Autosomal Dominant or X-linked Disorder Variant is de novo 2 0-3 12
Proband with predicted or proven null variant 1.5 0-2 10
Proband with other variant type with some evidence of gene impact 0.5 0-1.5 7
Autosomal Recessive Disease Two variants in trans and at least one de novo or a predicted/proven null variant 2 0-3 12 19
9.5
12
Costa C et al. 2003 Jan (PMID:12559850); Yang BZ et al. 2001 May (PMID:11350184); Hsu BY et al. 2001 Sep-Oct (PMID:11592821); Huizing M et al. 1998 Jun (PMID:9686371); IJlst L et al. 2001 Jan 26 (PMID:11162577); Iacobazzi V et al. 2004 Oct (PMID:15365988); Wang GL et al. 2011 Aug (PMID:21605995);
Two variants (not predicted/proven null) with some evidence of gene impact in trans 1 0-1.5 7
3.85
Costa C et al. 2003 Jan (PMID:12559850); Huizing M et al. 1997 Dec (PMID:9399886); Iacobazzi V et al. 2004 Oct (PMID:15365988); Wang GL et al. 2011 Aug (PMID:21605995);
Segregation Evidence   Summed LOD Family Count  
Candidate gene sequencing
Exome/genome or all genes sequenced in linkage region
Total Summed LOD Score    
Case-Control Data
Case-Control Study Type Case-Control Quality Criteria Guidelines Points PMIDs/Notes
Points/Study Max Count Points Counted
Single Variant Analysis 1. Variant Detection Methodology
2. Power
3. Bias and confounding
4. Statistical Significance
0-6 12
Aggregate Variant Analysis 0-6
Total Genetic Evidence Points (Maximum 12) 12
Experimental Evidence
Evidence Category Evidence Type Guidelines Points PMIDs/Notes
Default Range Max Count Total Counted
Function Biochemical Function 0.5 0 - 2 2 1
0.5
1
Indiveri C et al. 1998 Aug 28 (PMID:9731180);
Protein Interaction 0.5 0 - 2
Expression 0.5 0 - 2 1 0.5
Huizing M et al. 1997 Dec (PMID:9399886);
Functional Alteration Patient cells 1 0 - 2 2
Non-patient cells 0.5 0 - 1
Models Non-human model organism 2 0 - 4 4
Cell culture model 1 0 - 2
Rescue Rescue in human 2 0 - 4
Rescue in non-human model organism 2 0 - 4
Rescue in cell culture model 1 0 - 2
Rescue in patient cells 1 0 - 2
Total Experimental Evidence Points (Maximum 6) 1

 


 

Assertion criteria Genetic Evidence (0-12 points) Experimental Evidence
(0-6 points)
Total Points
(0-18)
Replication Over Time (Y/N)
Description Case-level, family segregation, or case-control data that support the gene-disease association Gene-level experimental evidence that support the gene-disease association Sum of Genetic & Experimental
Evidence
> 2 pubs w/ convincing evidence over time (>3 yrs)
Assigned Points 12 1 13 YES
CALCULATED CLASSIFICATION LIMITED 1-6
MODERATE 7-11
STRONG 12-18
DEFINITIVE 12-18 AND replication over time
Valid contradictory evidence (Y/N)*
NO
CALCULATED CLASSIFICATION (DATE)
Definitive
10/11/2018
EXPERT CURATION (DATE)
Definitive
05/22/2018